Alembic Pharmaceuticals has informed that the Board of Directors of the company at its meeting held today has approved Audited Financial Results for the quarter and financial year ended 31st March, 2021 and recommended a dividend of Rs 14 (700%) per Equity Share having face value of Rs 2 each, subject to approval of the Shareholders at the ensuing Annual General Meeting. The company has enclosed the following: A) consolidated Audited Financial Results for the quarter and financial year ended 31st March, 2021, consolidated Statement of Assets and Liabilities as at 31st March, 2021, consolidated Cash Flow Statement for the financial year ended 31st March, 2021, B) standalone Audited Financial Results for the quarter and financial year ended 31st March, 2021, standalone Statement of Assets and Liabilities as at 31st March, 2021, standalone Cash Flow Statement for the financial year ended 31st March, 2021, C) Auditor's Report on Consolidated and Standalone Financial Results, D) Press Release and E) Investor Presentation. The company has declared that the Statutory Auditors of the Company, KC Mehta & Co., has issued audit report with unmodified opinion on the Consolidated and Standalone Audited Financial Results of the Company for the financial year ended 31st March, 2021. This declaration is given in compliance with Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The time of commencement of the Board Meeting was 11:30 am and the time of conclusion was 2:00 pm.
The above information is a part of company’s filings submitted to BSE.
